Takeda Pharmaceutical Company Limited - Depositary Receipt (Common Stock)
DE ˙ DB ˙ US8740602052
12,80 € ↓ -0,10 (-0,78%)
2026-06-04
DEL PRIS
SecurityDE:TKDA / Takeda Pharmaceutical Company Limited - Depositary Receipt (Common Stock)
InstitutionSignaturefd, Llc
Latest Disclosed Ownership70,023 shares
Latest Disclosed Value $ 1,296,822
Signaturefd, Llc reports 6.59% increase in ownership of TKDA / Takeda Pharmaceutical Company Limited - Depositary Receipt (Common Stock)

On April 7, 2026 - Signaturefd, Llc filed a 13F-HR form disclosing ownership of 70,023 shares of Takeda Pharmaceutical Company Limited - Depositary Receipt (Common Stock) (DE:TKDA) valued at $1,106,363 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 20, 2026 disclosing 65,694 shares of Takeda Pharmaceutical Company Limited - Depositary Receipt (Common Stock). This represents a change in shares of 6.59% during the quarter. The current value of the position is $896,294 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-07 2026-03-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 70,023 4,329 6.59 1,297 26.56 0.0199
2026-01-20 2025-12-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 65,694 -15,089 -18.68 1,024 -13.37 0.0156
2025-10-21 2025-09-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 80,783 1,152 1.45 1,183 -3.98 0.0186
2025-07-16 2025-06-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 79,631 12,052 17.83 1,231 22.61 0.0210
2025-05-02 2025-03-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 67,579 2,482 3.81 1,005 16.61 0.0190
2025-02-10 2024-12-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 65,097 19,786 43.67 862 33.70 0.0163
2024-10-21 2024-09-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 45,311 10,070 28.57 644 41.23 0.0123
2024-07-29 2024-06-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 35,241 -14,900 -29.72 456 -34.48 0.0093
2024-05-03 2024-03-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 50,141 10,654 26.98 696 23.62 0.0147
2024-02-01 2023-12-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 39,487 -3,838 -8.86 563 -15.97 0.0130
2023-11-03 2023-09-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 43,325 -351 -0.80 670 -2.33 0.0175
2023-08-01 2023-06-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 43,676 523 1.21 686 -3.52 0.0175
2023-04-28 2023-03-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 43,153 14,538 50.81 711 59.42 0.0194
2023-01-30 2022-12-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 28,615 -6,688 -18.94 446 -2.62 0.0130
2022-11-08 2022-09-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 35,303 10,972 45.09 458 33.92 0.0157
2022-08-10 2022-06-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 24,331 -10,720 -30.58 342 -31.87 0.0116
2022-05-02 2022-03-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 35,051 13,052 59.33 502 67.33 0.0151
2022-01-25 2021-12-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 21,999 -1,957 -8.17 300 -23.47 0.0092
2021-10-28 2021-09-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 23,956 4,907 25.76 392 22.12 0.0135
2021-07-26 2021-06-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 19,049 951 5.25 321 -2.73 0.0128
2021-04-30 2021-03-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 18,098 2,018 12.55 330 12.63 0.0146
2021-02-11 2020-12-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 16,080 1,382 9.40 293 11.83 0.0138
2020-11-03 2020-09-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 14,698 951 6.92 262 6.50 0.0140
2020-07-30 2020-06-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 13,747 778 6.00 246 24.87 0.0149
2020-04-23 2020-03-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 12,969 -4,567 -26.04 197 -43.06 0.0170
2020-02-05 2019-12-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 17,536 3,351 23.62 346 41.80 0.0256
2019-10-16 2019-09-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 14,185 6,810 92.34 244 86.26 0.0200
2019-07-31 2019-06-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 7,375 -5,831 -44.15 131 -51.30 0.0113
2019-05-09 2019-03-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 13,206 12,676 2,391.70 269 2,888.89 0.0229
2019-02-13 2018-12-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 530 530 9 0.0008
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.